Trade Viridian Therapeutics, Inc. - VRDN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.08 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 13.39 |
| Open | 13.19 |
| 1-Year Change | -42.75% |
| Day's Range | 13.04 - 13.62 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 20, 2024 | 13.50 | 0.18 | 1.35% | 13.32 | 13.64 | 12.98 |
| May 17, 2024 | 13.39 | -0.86 | -6.04% | 14.25 | 14.32 | 13.36 |
| May 16, 2024 | 14.59 | 0.40 | 2.82% | 14.19 | 14.75 | 13.90 |
| May 15, 2024 | 14.23 | -0.56 | -3.79% | 14.79 | 15.23 | 14.16 |
| May 14, 2024 | 14.63 | 0.37 | 2.59% | 14.26 | 15.02 | 14.15 |
| May 13, 2024 | 14.31 | 0.43 | 3.10% | 13.88 | 14.66 | 13.88 |
| May 10, 2024 | 13.86 | -0.02 | -0.14% | 13.88 | 13.99 | 13.32 |
| May 9, 2024 | 13.87 | -0.26 | -1.84% | 14.13 | 14.29 | 13.25 |
| May 8, 2024 | 14.85 | -0.32 | -2.11% | 15.17 | 15.25 | 14.37 |
| May 7, 2024 | 15.09 | -0.10 | -0.66% | 15.19 | 15.72 | 14.87 |
| May 6, 2024 | 15.57 | 0.18 | 1.17% | 15.39 | 15.72 | 15.12 |
| May 3, 2024 | 15.34 | 0.36 | 2.40% | 14.98 | 15.44 | 14.95 |
| May 2, 2024 | 14.53 | 0.61 | 4.38% | 13.92 | 14.59 | 13.88 |
| May 1, 2024 | 13.76 | 0.58 | 4.40% | 13.18 | 14.33 | 13.09 |
| Apr 30, 2024 | 13.23 | 0.15 | 1.15% | 13.08 | 13.72 | 13.08 |
| Apr 29, 2024 | 13.56 | 0.83 | 6.52% | 12.73 | 13.59 | 12.55 |
| Apr 26, 2024 | 12.84 | 0.41 | 3.30% | 12.43 | 12.99 | 12.41 |
| Apr 25, 2024 | 12.67 | -0.06 | -0.47% | 12.73 | 12.84 | 12.16 |
| Apr 24, 2024 | 13.00 | -1.28 | -8.96% | 14.28 | 14.32 | 12.88 |
| Apr 23, 2024 | 14.21 | -0.11 | -0.77% | 14.32 | 14.95 | 14.20 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Viridian Therapeutics, Inc. Company profile
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. (Viridian) is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company’s products include VRDN-001 and VRDN-002. The Company’s advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R). The IGF-1R is a clinically and commercially validated target for the treatment of thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. The Company’s product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology. The VRDN-002 is designed to support the administration as a convenient, low-volume, subcutaneous injection.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Viridian Therapeutics Inc revenues increased from $1.1M to $3M. Net loss decreased 28% to $79.4M. Revenues reflect Collaboration revenue increase from $735K to $3M. Lower net loss reflects Acquired in-process research and develop decrease from $69.9M (expense) to $0K, Interest and other expense decrease of 99% to $3K (expense), Interest and other income increase of 84% to $318K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
221 Crescent Street
Bldg. 17, Suite 401
WALTHAM
MASSACHUSETTS 02453
US
News
Disinflation resumes in the US as CPI drops in April
The rate of growth in US consumer prices dropped in April leading markets to price in more chances of rate cuts from the Fed
11:24, 16 May 2024
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024
Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com